Immune Targeting Systems Ltd Report issue

For profit Phase 1 Phase 2
Founded: London United Kingdom (2003)
Status: Acquired by Altimmune, Inc. (2015)

Organization Overview

First Clinical Trial
2010
NCT01265914
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2014

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree